Cardiovascular Drugs and Therapy最新文献

{"title":"Allopurinol for Marfan Aortopathy: Pharmacogenomic Safety and Sex-Stratified Trial Design Warrant Consideration.","authors":"Tahir Ullah, Muhammad Tariq Shah","doi":"10.1007/s10557-026-07971-7","DOIUrl":"https://doi.org/10.1007/s10557-026-07971-7","url":null,"abstract":"<p><p>A recent review by Egea et al. presents a compelling case for adding allopurinol to standard beta-blocker/ARB therapy in Marfan syndrome (MFS) aortopathy, drawing on consistent preclinical evidence and the drug's recent European Medicines Agency orphan-drug designation. This letter identifies two gaps that are genuinely absent from that review and could materially affect the safety and interpretability of any future allopurinol trial in MFS. First, the review discusses allopurinol hypersensitivity syndrome, toxic epidermal necrolysis, and Stevens-Johnson syndrome only as background toxicology, without proposing pre-treatment pharmacogenomic (HLA-B*58:01) or renal-function screening, despite targeting a population typically treated from childhood for years or indefinitely; real-world data show that guideline-recommended testing is not reliably performed even where quality-improvement measures exist. Second, the review's own preclinical data reveal a sex-dimorphic allopurinol treatment effect and sex-dependent aneurysm severity that are never translated into a recommendation for sex-stratified trial design, a concern reinforced by recent evidence of sex-specific, sometimes opposing, vascular responses to comparable Marfan pharmacotherapies and by sex-specific patterns in the serum urate-cardiovascular outcome relationship. Both gaps are correctable at the design stage rather than reflecting flaws in the underlying rationale. We recommend that future allopurinol-MFS trials incorporate risk- or ancestry-based pharmacogenomic screening alongside renal-function assessment, together with prospective balanced enrollment, stratified randomization, and prespecified sex-by-treatment interaction analyses, to ensure a safe and conclusive test of allopurinol's role in Marfan aortopathy management.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"METTL3 Confers Ischemia/Reperfusion-Caused Myocardial Injury by Triggering Ferroptosis via Regulating the lncRNA SNHG14/miR-195a-5p/ACSL4 Axis.","authors":"Guorong Lai, Jie Yang, Mailin Zhao, Liangxian Zhu, Dongsheng Le, Li Liu, Chao Zhang, Fan Yang, Jian Wen, Shikai Gui, Yanhui Hu, Yingping Liang","doi":"10.1007/s10557-026-07961-9","DOIUrl":"https://doi.org/10.1007/s10557-026-07961-9","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is recognized as a key inducer of myocardial ischemia-reperfusion injury (MIRI). Methyltransferase-like 3 (METTL3) was widely reported to participate in regulating ferroptosis, whereas, the effect and mechanism of METTL3 in ferroptosis following MIRI remain unclear.</p><p><strong>Methods: </strong>A myocardial ischemia/reperfusion (I/R) mouse model was established and infarct area was assessed by TTC staining. HE and immunohistochemistry evaluated myocardial damage and oxidative stress. Serum myocardial injury markers including (TnT, CK-MB, LDH) were detected by ELISA. Primary mouse cardiomyocytes were cultured under hypoxia/reoxygenation (H/R) condition. RNA and protein levels were evaluated via qRT-PCR and Western blot, respectively. Cell survival, Fe²⁺ content and oxidative stress were tested by CCK-8, ELISA and DCFH-DA assay, respectively. Global m6A levels were tested by the colorimetric m6A detection assay. RIP, RNA pull-down and dual-luciferase assay verified molecular interactions.</p><p><strong>Results: </strong>The global m6A modification level and the expression of \"writer\" proteins, including METTL3, METTL14, and WTAP, were increased in cardiac tissues after I/R injury. Moreover, downregulation of METTL3 relieved myocardial injury and ferroptosis in I/R mice and H/R-induced cardiomyocytes. Mechanistically, METTL3 directly interacted with long non-coding RNA SNHG14 (lncRNA SNHG14) and upregulated its expression by catalyzing m6A modification. LncRNA SNHG14 overexpression compromised the protective effect of METTL3 knockdown on H/R-induced cardiomyocyte ferroptosis. Moreover, lncRNA SNHG14 functioned as a miR-195a-5p sponge, enhancing ACSL4 expression. Knockdown of miR-195a-5p reversed the protective roles of METTL3/lncRNA SNHG14 silencing on cardiomyocytes ferroptosis.</p><p><strong>Conclusion: </strong>Our results reveal that METTL3 promoted cardiomyocyte ferroptosis after MIRI through regulating the lncRNA SNHG14/miR-195a-5p/ACSL4 axis signaling pathway, which provides new therapeutic targets for MIRI treatment.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting Anemia-Associated Risk after Elective Percutaneous Coronary Intervention.","authors":"Abdullah Sarıhan, Mücahit Aker, Macit Kalçık","doi":"10.1007/s10557-026-07841-2","DOIUrl":"10.1007/s10557-026-07841-2","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2079-2080"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications.","authors":"Min Zhong, Xin Wu, Yu Liu, Yirun Mao, Meng Liu, Xing Liu, Qin Liu","doi":"10.1007/s10557-026-07882-7","DOIUrl":"10.1007/s10557-026-07882-7","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1993-2008"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative and Long-Term Cardiorenal Outcomes of SGLT2 Inhibitors in Cardiac Surgery Patients: A Systematic Review and Meta-Analysis.","authors":"Najaf Ahmed Rajpar, Shehdev Meghwar, Rayyan Nabi, Sanya Ashraf Khaskheli, Sameen Khan, Aamna Rehman, Marhaba Fatima, Sabahat Ul Ain Munir Abbasi, Nafhat Shaikh, Zahid Nabi, Saeed Ahmed, Raheel Ahmed","doi":"10.1007/s10557-026-07848-9","DOIUrl":"10.1007/s10557-026-07848-9","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1781-1792"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Single Antiplatelet, Dual Antiplatelet, and Anticoagulation Plus Antiplatelet Therapy on Branch Vessel Patency and Bleeding Risk Following Branched Endovascular Aortic Repair.","authors":"Lu Ye, Longbao Zhao, Xiaoling Xie, Juanping Zhang, Long Yang","doi":"10.1007/s10557-026-07886-3","DOIUrl":"10.1007/s10557-026-07886-3","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effects of single antiplatelet (SAPT), dual antiplatelet (DAPT), and anticoagulation plus antiplatelet (AC + AP) therapies on branch vessel patency and bleeding risk after branched endovascular aortic repair (B-EVAR).</p><p><strong>Methods: </strong>This single-center retrospective cohort study included 250 patients with 880 target branches who underwent B-EVAR (2015-2025). Primary outcomes were branch patency loss (occlusion/stenosis requiring reintervention) and major bleeding (ISTH criteria). Propensity score weighting and competing risk regression controlled confounding.</p><p><strong>Results: </strong>During median 18-month follow-up, 82 branches (9.3%) lost patency: 12.0% (SAPT), 7.0% (DAPT), 7.5% (AC + AP). DAPT significantly improved patency vs. SAPT (sHR 0.72, p = 0.045). Major bleeding occurred in 22 patients (8.8%): 4.4% (SAPT), 7.5% (DAPT), 22.5% (AC + AP). AC + AP tripled bleeding risk (HR 3.10, p = 0.001); DAPT showed non-significant trend (HR 1.62, p = 0.13).</p><p><strong>Conclusion: </strong>DAPT provided the most favorable balance between branch vessel patency and major bleeding after B-EVAR. AC + AP was associated with substantially higher bleeding and should be reserved for patients with an independent indication for anticoagulation. Taken together with prior multicenter European and US consortium data, these findings support a class IB-level preference for DAPT in patients without competing anticoagulation needs; prospective randomized multicenter trials are needed to support a class IA recommendation.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1825-1837"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally Invasive Trans-atrial Mitral Valve Replacement Using a Balloon-expandable Transcatheter Valve in the Setting of Severe Mitral Annular Calcification.","authors":"Syed B Peer, Prakash Jayanthi, Zachary Gray, Aladdein Mattar, Guilherme Silva, Srikanth Koneru, Kenneth Liao","doi":"10.1007/s10557-025-07804-z","DOIUrl":"10.1007/s10557-025-07804-z","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1763-1769"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Peripheral Immune Signatures to Cardiac Remodeling: Interpreting the Monocyte Axis in Hypertension-Related Atrial Fibrillation.","authors":"Zhongyang Zhang, Shen Wang","doi":"10.1007/s10557-026-07888-1","DOIUrl":"10.1007/s10557-026-07888-1","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2095-2096"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?","authors":"Mingyue Chen, Yan Han, Fenxiang Zhang","doi":"10.1007/s10557-026-07832-3","DOIUrl":"10.1007/s10557-026-07832-3","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2087-2088"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Dapagliflozin Combined with Sacubitril/Valsartan on Cardiac Electrophysiology and Quantitative Myocardial Motion Parameters in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction.","authors":"Tao Wang, Xiaoli Chen, Huimin Wang, Mengyu Zhang","doi":"10.1007/s10557-026-07892-5","DOIUrl":"10.1007/s10557-026-07892-5","url":null,"abstract":"<p><strong>Background: </strong>Patients with concomitant atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) face significant morbidity and limited therapeutic options. This retrospective cohort study evaluated the effects of dapagliflozin combined with sacubitril/valsartan on cardiac electrophysiological and myocardial motion parameters in this population.</p><p><strong>Methods: </strong>Data from 292 patients treated between January 2022 and December 2024 were analyzed. Patients received either sacubitril/valsartan alone (SVC Group, n = 154) or combined with dapagliflozin (D + SVC Group, n = 138). At baseline and at 6 months, cardiac structure/function, electrophysiology, biomarkers, and functional capacity were assessed, in addition to the evaluation of clinical events and safety.</p><p><strong>Results: </strong>Baseline characteristics were comparable between groups. After 6 months, the D + SVC Group demonstrated significantly greater improvements in left atrial volume index (LAVI, p < 0.001), left ventricular ejection fraction (LVEF, p = 0.004), left ventricular mass index (LVMI, p = 0.011), left atrial diameter (LAD, p = 0.009), E/e' ratio (p < 0.001), heart rate variability indices (p < 0.05), P-wave duration (PWD, p = 0.008), P-wave dispersion (PD, p = 0.002), P-terminal force in V1 (PTFV1, p < 0.001), NT-proBNP (p < 0.001), NLR (p < 0.001), hs-CRP levels (p < 0.001), 6-minute walk distance (p = 0.002), and Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 scores (p < 0.001) than the SVC Group. The D + SVC group exhibited reduced rates of HF rehospitalization (p = 0.026) and cardiovascular death (p = 0.030), along with a greater reduction in AF burden (p < 0.001).</p><p><strong>Conclusion: </strong>These findings suggest that adding dapagliflozin to sacubitril/valsartan may provide additional benefits for these patients.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1849-1860"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}